{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06200233","nct_id":"NCT06200233","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06200233. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Rivoceranib 700 mg once daily by mouth. Rivoceranib should be given at the same time each day, with or without meals. Swallow the tablet whole. Do not chew, crush, or split the tablet.\n\nReceive study medication until there is evidence of disease progression, intolerable toxicity, withdrawal of consent by the patient, or in the judgment of the principal investigator that the study cannot continue due to inability to administer.\n\nTumor response will be assessed according to RECIST v1.1 criteria based on imaging studies (CT or MRI) measured every 8 weeks (±1 week) from C1D1 through 12 months and every 12 weeks (±1 week) after 12 months.","label":"single arm","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-01","type":"ESTIMATED"},"conditions":["Thymic Epithelial Tumor"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Rivoceranib","otherNames":[],"type":"DRUG"}],"last_update":"2024-04-09","lead_sponsor":"Samsung Medical Center","official_title":"A Phase II, Open-label, Single-arm, Multi-center Clinical Trial of Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-03-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective response rate(ORR) Objective response rate(ORR)","timeFrame":"6 month after completion of enrollment"}],"references":[],"start_date":{"date":"2024-05-01","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor","url":"https://clinicaltrials.gov/study/NCT06200233"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06200233"}